Topics

Castleman Disease Collaborative Network (CDCN) Company Profile

10:30 EST 21st January 2020 | BioPortfolio

CDCN is a global initiative dedicated to accelerating research and treatment for Castleman disease (CD) to improve survival for all patients with CD. The CDCN’s innovative approach first involved building a global community of over 400 physicians and researchers, assembling a scientific advisory board of 28 experts from eight countries, and supporting and engaging patients in research prioritization. Then, the CDCN crowdsourced among the global community to identify gaps in medical knowledge and determine high priority research projects. In parallel, the CDCN connects and supports thousands of CD patients around the world. Now, the CDCN recruits top researchers to conduct studies, and works with patients, loved ones, and the public to raise funding to enable these studies. More information is available at: www.CDCN.org


News Articles [949 Associated News Articles listed on BioPortfolio]

Collaborative Study Using Medidata Rave Omics Leads to Discovery of Potential Biomarkers for Early Response to Treatment in Castleman Disease

New research presented at the 61st Annual Meeting of the American Society of Hematology Medidata, a Dassault Systèmes company, is collaborating with the Castleman Disease Collaborative Network ...

Medidata Institute Redefines Technology’s Role in Advancing Science and Healthcare

Institute collaborates with leading influencers in life sciences to solve industry challenges and provide fresh perspectives Initial partnerships with Ca...

CURE Media Group Announces David C. Fajgenbaum as Guest Speaker at the 2019 MPN Heroes® Recognition Ceremony

Event recognizes individuals dedicated to empowering people affected by myeloproliferative neoplasms CURE Media Group, which reaches over 1 million patients, survivors and caregivers across an indus...

Treatment doctor tested on himself can put others into remission

Castleman Disease patients who do not respond to the only drug currently approved by the FDA may have another option that targets a specific pathway called PI3K/Akt/mTOR.

American College of Cardiology to Launch Ambulatory Chronic Disease Network

The American College of Cardiology and Veradigm have announced a strategic partnership create the largest ambulatory chronic disease network in the United States with more than 250,000 clinicians an...

Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies

BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.    

NIH forms new collaborative influenza vaccine research network

The CIVICs program is a new network of research centers that will work together to develop more durable, broadly protective and longer-lasting influenza vaccines.

5 Key Features of Successful Quality Collaboratives

Evan Osborne, MPH, Manager at Dacarba LLC Quality collaboratives are comprised of multiple teams working together from different domains within the healthcare industry. Payors and providers have shown...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Sylvant [janssen biotech, inc.]

These highlights do not include all the information needed to use SYLVANT safely and effectively. See full prescribing information for SYLVANT. SYLVANT (siltuximab) for injection, for intravenous use ...

PubMed Articles [4279 Associated PubMed Articles listed on BioPortfolio]

Mesenteric Castleman's disease mimicking neuroendocrine tumour.

Castleman's disease is a rare entity and is a benign hyperplastic enlargement of lymph nodes. It can occur anywhere within the body but only approximately 50 cases of mesenteric Castleman's disease ha...

Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report.

Castleman's disease (CD) is a rare lymphoproliferative disease. Compared to unicentric CD, multicentric Castleman disease (MCD) displays poorer prognosis and great variance to different therapies. Tho...

Castleman Disease of the Parotid Gland: A Case Report.

Castleman disease is a rare lymphoproliferative disorder characterized by the formation of painless hyperplastic lymph nodes. It can affect any lymph nodes of the body but rarely affects the salivary...

Multicentric Castleman disease with TAFRO syndrome and Sjögren's.

We describe a patient with Castleman's disease with TAFRO syndrome and concurrent Sjögren's syndrome and investigate whether the autoimmune process may have accelerated the onset of her Castleman's d...

Diagnosis and Management of Castleman Disease.

Castleman disease is a heterogeneous nonmalignant lymphoproliferative disorder. Major distinctions include unicentric versus multicentric presentation; hyaline vascular, plasmacytic, or mixed patholog...

Clinical Trials [4861 Associated Clinical Trials listed on BioPortfolio]

International Registry for Patients With Castleman Disease

The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease...

Unlock the Cell: Castleman's Disease Flow Cytometry Study

The purpose of this study is to study stained Castleman's Disease lymph nodes and perform flow cytometry and cell culture experiments on Castleman Disease blood samples to determine which ...

Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.

A Study of the Safety and Efficacy of CNTO 328 in Combination With Best Supportive Care Compared to Best Supportive Care in Patients With Multicentric Castleman's Disease

The study is being conducted to demonstrate that CNTO 328 in combination with best supportive care is superior to best supportive care in terms of durable tumor and symptomatic response (r...

BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)

To explore the effectiveness and safety of bortezomib, cyclophosphamide and dexamethasone (BCD regimen) in newly diagnosed idiopathic Multicentric Castleman's disease (iMCD) patients.

Companies [2064 Associated Companies listed on BioPortfolio]

Castleman Disease Collaborative Network (CDCN)

CDCN is a global initiative dedicated to accelerating research and treatment for Castleman disease (CD) to improve survival for all patients with CD. The CDCN’s innovative ap...

Children's Rare Disease Network

The Children's Rare Disease Network (CDRN) is a non-profit advocacy group committed to connecting, educating and empowering the rare disease community, providing a link between families impacted by ra...

Eastside Health Network

The Eastside Health Network is a clinically integrated network of physicians and providers who share a collaborative approach to health care delivery that manages patients’ c...

Vascular Cures

The Vascular Cures Research Network is a national research consortium of up to 12 world-class medical institutions. Members of this collaborative team share information and result...

CNS Network

CNS Network, Inc is dedicated to furthering the knowledge and application of psychiatric medications. We perform trials investigating the efficacy of medications for depression, schizophrenia, bipolar...

More Information about "Castleman Disease Collaborative Network (CDCN)" on BioPortfolio

We have published hundreds of Castleman Disease Collaborative Network (CDCN) news stories on BioPortfolio along with dozens of Castleman Disease Collaborative Network (CDCN) Clinical Trials and PubMed Articles about Castleman Disease Collaborative Network (CDCN) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Castleman Disease Collaborative Network (CDCN) Companies in our database. You can also find out about relevant Castleman Disease Collaborative Network (CDCN) Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record